Market Closed -
Nasdaq
21:00:00 01/05/2024 BST
|
5-day change
|
1st Jan Change
|
0.642
USD
|
-2.04%
|
|
+3.57%
|
-52.44%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
296.3
|
373.8
|
29.39
|
36.73
|
23.04
|
-
|
-
|
Enterprise Value (EV)
1 |
363.1
|
411.8
|
29.39
|
36.73
|
23.04
|
23.04
|
23.04
|
P/E ratio
|
-0.76
x
|
-0.81
x
|
-0.66
x
|
-0.17
x
|
-0.44
x
|
-0.51
x
|
-0.46
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.99
x
|
6.17
x
|
96.4
x
|
9,183
x
|
7,679
x
|
9.21
x
|
4.19
x
|
EV / Revenue
|
3.99
x
|
6.17
x
|
96.4
x
|
9,183
x
|
7,679
x
|
9.21
x
|
4.19
x
|
EV / EBITDA
|
-1.59
x
|
-3.21
x
|
-0.48
x
|
-0.55
x
|
-0.31
x
|
-0.29
x
|
-0.25
x
|
EV / FCF
|
-1,735,677
x
|
-2,220,455
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-1.37
x
|
-2.37
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
2,232
|
7,154
|
8,927
|
27,209
|
35,884
|
-
|
-
|
Reference price
2 |
132.8
|
52.25
|
3.292
|
1.350
|
0.6420
|
0.6420
|
0.6420
|
Announcement Date
|
18/03/21
|
28/03/22
|
30/03/23
|
26/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
144
|
74.31
|
60.61
|
0.305
|
0.004
|
0.003
|
2.502
|
5.5
|
EBITDA
1 |
-
|
-186.5
|
-116.4
|
-60.87
|
-66.59
|
-75.4
|
-80.5
|
-91.3
|
EBIT
1 |
-
|
-195.2
|
-117.8
|
-61.78
|
-67.14
|
-67.05
|
-69.71
|
-91.3
|
Operating Margin
|
-
|
-262.66%
|
-194.42%
|
-20,256.07%
|
-1,678,575%
|
-2,234,900%
|
-2,785.71%
|
-1,660%
|
Earnings before Tax (EBT)
1 |
-
|
-230.1
|
-178.6
|
-49.25
|
-124.4
|
-68.12
|
-77.19
|
-97.1
|
Net income
1 |
-148
|
-192.8
|
-247.4
|
-38.16
|
-124.1
|
-68.12
|
-77.19
|
-97.1
|
Net margin
|
-102.81%
|
-259.44%
|
-408.21%
|
-12,510.49%
|
-3,102,875%
|
-2,270,733.33%
|
-3,084.42%
|
-1,765.45%
|
EPS
2 |
-
|
-175.2
|
-64.25
|
-5.000
|
-7.870
|
-1.460
|
-1.270
|
-1.390
|
Free Cash Flow
|
-
|
-170.7
|
-168.3
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-229.69%
|
-277.75%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/20
|
18/03/21
|
28/03/22
|
30/03/23
|
26/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
9.718
|
7.66
|
1.375
|
0.104
|
0.08
|
0.014
|
-
|
0.002
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-37.42
|
-
|
-19.91
|
-14.21
|
-13.89
|
-13.31
|
-
|
-14.77
|
-23.2
|
-13.23
|
-14.9
|
-17.5
|
-20.1
|
-22.8
|
EBIT
|
-37.52
|
-20.16
|
-21.76
|
-14.21
|
-13.89
|
-13.47
|
-
|
-
|
-23.32
|
-13.34
|
-
|
-
|
-
|
-
|
Operating Margin
|
-386.1%
|
-263.17%
|
-1,582.69%
|
-13,663.46%
|
-17,358.75%
|
-96,207.14%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-43.74
|
-82.91
|
-13.81
|
-6.834
|
-14.72
|
-13.21
|
-
|
-17.8
|
-73.45
|
-15.73
|
-13.7
|
-16.5
|
-19.2
|
-21.9
|
Net income
1 |
-43.74
|
-92.87
|
-13.81
|
-5.513
|
-5.114
|
-13.72
|
-
|
-17.81
|
-73.45
|
-15.41
|
-13.7
|
-16.5
|
-19.2
|
-21.9
|
Net margin
|
-450.13%
|
-1,212.45%
|
-1,004.22%
|
-5,300.96%
|
-6,392.5%
|
-98,014.29%
|
-
|
-890,350%
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-11.50
|
-14.00
|
-2.000
|
-0.7500
|
-0.7500
|
-1.640
|
-1.590
|
-1.470
|
-4.890
|
-0.6200
|
-0.4500
|
-0.4600
|
-0.5200
|
-0.4900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/11/21
|
28/03/22
|
10/05/22
|
15/08/22
|
14/11/22
|
30/03/23
|
15/05/23
|
14/08/23
|
13/11/23
|
26/03/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
66.8
|
38
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-0.3583
x
|
-0.3264
x
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-171
|
-168
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-150%
|
-188%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
128.3
|
131.6
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-97.20
|
-22.10
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-151.0
|
-43.50
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
4.94
|
0.86
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
6.65%
|
1.41%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/20
|
18/03/21
|
28/03/22
|
30/03/23
|
26/03/24
|
-
|
-
|
-
|
Last Close Price
0.642
USD Average target price
10.3
USD Spread / Average Target +1,504.36% Consensus |
1st Jan change
|
Capi.
|
---|
| -52.44% | 23.04M | | -1.17% | 104B | | +2.87% | 97.47B | | +2.13% | 22.25B | | -14.77% | 21.68B | | -8.79% | 18.2B | | -39.98% | 17.02B | | -13.21% | 16.36B | | +8.55% | 14.39B | | +35.75% | 12.37B |
Bio Therapeutic Drugs
|